手法を比較

	適応型第IV相試験	適応型第III相臨床試験
分野	疫学	疫学
系統	Process / pipeline	Process / pipeline
提唱年	1990s–2000s (regulatory formalization of adaptive Phase IV designs)	1969–2019 (sequential testing roots ~1969; formal adaptive design guidance 2010–2019)
提唱者	Adaptive design principles developed by multiple statisticians; Phase IV framework established by regulatory bodies (FDA, EMA) in the late 20th century	Methodological foundations by Armitage et al. (1969); modern adaptive framework codified by FDA and ICH guidance (2010s)
種類	Adaptive post-marketing clinical study design	Interventional confirmatory clinical trial with pre-specified interim adaptations
原典	Chow, S. C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman and Hall/CRC. ISBN: 978-1584889625	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2019). ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. ICH Harmonised Guideline.
別名	adaptive post-marketing surveillance study, adaptive pharmacovigilance study, adaptive Phase IV trial, adaptive post-approval study	adaptive confirmatory trial, seamless Phase II/III adaptive trial, adaptive pivotal trial, adaptive design Phase III
関連	6	6
概要	An Adaptive Phase IV study is a post-marketing surveillance study conducted after a drug or intervention has received regulatory approval, augmented with pre-specified adaptive design elements that allow pre-planned modifications to the study protocol in response to accumulating data. These modifications may include sample size re-estimation, endpoint adjustments, or population enrichment, all governed by statistical rules set before the study begins, preserving scientific integrity while increasing efficiency.	An adaptive Phase III clinical trial is a confirmatory randomized controlled trial that incorporates pre-specified rules allowing modifications to the trial design — such as sample size re-estimation, dose selection, or population enrichment — based on accumulating interim data, while preserving the Type I error rate. It sits at the top of the evidence hierarchy and is used to obtain regulatory approval of new interventions.